<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236129</url>
  </required_header>
  <id_info>
    <org_study_id>P140303</org_study_id>
    <secondary_id>2016-A00645-46</secondary_id>
    <nct_id>NCT03236129</nct_id>
  </id_info>
  <brief_title>Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells</brief_title>
  <acronym>DLI-Boost</acronym>
  <official_title>Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells: A Confirmatory, Randomized, Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the
      possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with
      hematological malignancies who had never shown any signs of GVHD after transplant or after
      one or more DLI.

      The Investigators, we plan to demonstrate the benefit of Treg-depleted DLI as compared to the
      reference treatment of relapse in hematological malignancies after allogeneic HSCT which is
      currently based on standard DLI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is designed to demonstrate the benefit of Treg-depleted DLI as compared
      to the reference treatment of relapse in hematological malignancies after allogeneic HSCT
      which is currently based on standard DLI.

      Patients who have never shown any signs of GVHD and for which one (or more) unmanipulated DLI
      have been ineffective. Those patients will receive a subsequent DLI, which will be either
      unmanipulated (control arm) or Treg depleted (experimental arm) after a randomization. In
      both cases, the second DLI will be immediately preceded by a lymphodepleting treatment based
      on cyclophosphamide and fludarabine association.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of clinical manifestations of GVHD, in the form of acute GVHD with grade ≥ 2 and/or extensive chronic. This parameter will take into account the competitive risk of death unrelated to the GVHD</measure>
    <time_frame>1 year after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse, taking into account the competitive risk of death unrelated to relapse</measure>
    <time_frame>1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Regulatory T Cell Depletion</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>Treg depleted DLI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unmanipulated DLI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-reg depleted DLI</intervention_name>
    <description>The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes</description>
    <arm_group_label>Treg depleted DLI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard DLI</intervention_name>
    <description>The patients in this arm benefit of a standard DLI.</description>
    <arm_group_label>Unmanipulated DLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adults regardless of age or weight allograft for primary or secondary
             acute leukemia, MDS, lympho-proliferative syndrome (CLL, Myeloma, Lymphoma) or
             myelo-proliferative syndrome.

          -  Prior allogeneic HSCT (myeloablative or non-myeloablative conditioning) from a family
             donor geno-identical HLA or a volunteer donor HLA 10/10 or 9/10.

          -  Molecular, cytogenetic, cytological relapse regardless of the date after the
             transplant.

          -  Previous standard DLI should have brought a total dose of at least 5.106 CD3 + / kg
             (donor HLA-geno idendique) or 2.106 CD3 + / kg (voluntary donor).

          -  Patient corresponding to the failure criteria of a previous standard DLI, defined for
             each type of hematological malignancies in the test model &quot;DLI-Treg-1&quot; after a delay
             of at least 30 days in the case of a progressive disease after DLI and at least 60
             days in the case of stable disease (due to possible delayed responses after DLI).

          -  Patient consented to the study (the consent of both parents will be collected for
             minors)

          -  Patients insured by a social security system.

          -  Negative pregnancy test (β-HCG hormone) within the 7 days prior to enrollment

        Exclusion Criteria:

          -  Presence of acute GVHD grade&gt; II or extensive chronic GVHD since the first DLI

          -  Patient receiving immunosuppressive therapy for the treatment of GVHD or other reason

          -  Impairment of liver function (transaminases&gt; 5 N or bilirubin&gt; 50 µM except Gilbert's
             disease) or renal function (creatinine clearance &lt;30 ml / min)

          -  OMS performance status &gt; 2

          -  Non controlled severe infection

          -  Patient under tutorship, curatorship or legal protection

        Donor Inclusion Criteria

          -  Being the initial HSC donor (HLA geno-identical family or non-family HLA 10/10 or
             9/10)

          -  Weight ≥20 kg authorizing the lymphapheresis

          -  Having no contra-indications for donating blood

          -  Absence of severe heart failure, unstable heart disease, uncontrolled hypertension,
             type 1 diabetes

          -  Negative serology for HIV1-2, HBV, HCV, HTLV 1 and VDRL/TPHA in the 30 days prior to
             apheresis. Negative viral genomics diagnosis is required for HIV, HBV and HCV

          -  Being informed of the study, and have given an oral non opposition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence BEKCERICH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence BECKERICH, MD</last_name>
    <phone>(0)1 49 81 20 57</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.beckerich@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sébastien MAURY, MD/ PhD</last_name>
    <phone>(0)1 49 81 20 57</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.maury@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien VANHOYE, PhD</last_name>
      <phone>(0)1 44 84 17 93</phone>
      <phone_ext>+33</phone_ext>
      <email>damien.vanhoye@drc.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia GREGOIRE, M. Sc</last_name>
      <phone>(0)1 49 81 41 64</phone>
      <phone_ext>+33</phone_ext>
      <email>Laetitia.gregoire@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302.</citation>
    <PMID>20650872</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLI</keyword>
  <keyword>Regulatory T cells depletion</keyword>
  <keyword>Hematological malignancies</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

